Sun Pharma's Dadra Unit Receives USFDA Warning Letter
USFDA issues warning letter to Sun Pharma's Dadra unit for violating manufacturing norms.
Sun Pharmaceutical Industries Ltd. received a warning letter from the US health regulator for its Dadra facility over a violation of manufacturing norms.
The warning letter by the US Food and Drug Administration summarises violations with respect to current good manufacturing practice regulations, the company said in an exchange filing on Wednesday.
The contents of the warning letter issued by the US health regulator shall be made public in due course, it added.
This intimation is further to our communication dated Apr. 11, 2024, about the Dadra facility receiving OAI status from the USFDA.
On Apr. 11, Sun Pharma informed stock exchanges that its Dadra facility had received official action-indicated status from the USFDA.
It followed an inspection at the company's Dadra facility from December 4 to Dec. 15, 2023.
(With Inputs From PTI)
